As doctors received more money from the company that sells an expensive drug known as Acthar Gel, the number of prescriptions written climbed and Medicare spending rose substantially, suggesting the payments swayed medical practice and cost taxpayers a bundle, according to a new analysis.

Specifically, for every $10,000 that Mallinckrodt (MNK) paid physicians in 2015, Medicare spending rose by 7.9 percent, or $53,000, for the drug, which is used to treat infantile spasms but often prescribed for more than a dozen other maladies as well. All totaled, Medicare spent more than $500 million on the drug that year. The analysis, which appeared in the JAMA Network Open, examined payments to three types of specialists: nephrologists, neurologists, and rheumatologists.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • The company way not ‘have it backwards’ – “They rationalize the high price, because they’re using all that revenue to do the research to fill in the evidence gaps.” But, allowing for inflation the 1990 price should be about $41 USD. Now the remaining 99.998 % of the increase is “because they can.”

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy